Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

Hervé Bonnefoi; Anil Potti; Mauro Delorenzi; Louis Mauriac; Mario Campone; Michèle Tubiana-Hulin; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Véronique Becette; Pierre Farmer; Sylvie André; Chaitanya R Acharya; Sayan Mukherjee; David Cameron; Jonas Bergh; Joseph R Nevins; Richard D Iggo

doi:10.1016/S1470-2045(07)70345-5

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, Louis Mauriac, Mario Campone, Michèle Tubiana-Hulin, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Véronique Becette, Pierre Farmer, Sylvie André, Chaitanya R Acharya, Sayan Mukherjee, David Cameron, Jonas Bergh, Joseph R Nevins, Richard D Iggo

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial.

Original language	English
Pages (from-to)	1071-8
Number of pages	8
Journal	The Lancet Oncology
Volume	8
Issue number	12
DOIs	https://doi.org/10.1016/S1470-2045(07)70345-5
Publication status	Published - Dec 2007

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemotherapy, Adjuvant
Cyclophosphamide
Disease-Free Survival
Epirubicin
Female
Fluorouracil
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genetic Testing
Humans
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Oligonucleotide Array Sequence Analysis
Patient Selection
Predictive Value of Tests
ROC Curve
Receptors, Estrogen
Reproducibility of Results
Sensitivity and Specificity
Taxoids
Treatment Outcome

Access to Document

10.1016/S1470-2045(07)70345-5

Cite this

Bonnefoi, H., Potti, A., Delorenzi, M., Mauriac, L., Campone, M., Tubiana-Hulin, M., Petit, T., Rouanet, P., Jassem, J., Blot, E., Becette, V., Farmer, P., André, S., Acharya, C. R., Mukherjee, S., Cameron, D., Bergh, J., Nevins, J. R., & Iggo, R. D. (2007). Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. The Lancet Oncology, 8(12), 1071-8. https://doi.org/10.1016/S1470-2045(07)70345-5

@article{6635c6f704f447e8b2b020fea0603863,

title = "Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial",

abstract = "We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Disease-Free Survival, Epirubicin, Female, Fluorouracil, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genetic Testing, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Oligonucleotide Array Sequence Analysis, Patient Selection, Predictive Value of Tests, ROC Curve, Receptors, Estrogen, Reproducibility of Results, Sensitivity and Specificity, Taxoids, Treatment Outcome",

author = "Herv{\'e} Bonnefoi and Anil Potti and Mauro Delorenzi and Louis Mauriac and Mario Campone and Mich{\`e}le Tubiana-Hulin and Thierry Petit and Philippe Rouanet and Jacek Jassem and Emmanuel Blot and V{\'e}ronique Becette and Pierre Farmer and Sylvie Andr{\'e} and Acharya, {Chaitanya R} and Sayan Mukherjee and David Cameron and Jonas Bergh and Nevins, {Joseph R} and Iggo, {Richard D}",

year = "2007",

month = dec,

doi = "10.1016/S1470-2045(07)70345-5",

language = "English",

volume = "8",

pages = "1071--8",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "12",

}

Bonnefoi, H, Potti, A, Delorenzi, M, Mauriac, L, Campone, M, Tubiana-Hulin, M, Petit, T, Rouanet, P, Jassem, J, Blot, E, Becette, V, Farmer, P, André, S, Acharya, CR, Mukherjee, S, Cameron, D, Bergh, J, Nevins, JR & Iggo, RD 2007, 'Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial', The Lancet Oncology, vol. 8, no. 12, pp. 1071-8. https://doi.org/10.1016/S1470-2045(07)70345-5

TY - JOUR

T1 - Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy

T2 - a substudy of the EORTC 10994/BIG 00-01 clinical trial

AU - Bonnefoi, Hervé

AU - Potti, Anil

AU - Delorenzi, Mauro

AU - Mauriac, Louis

AU - Campone, Mario

AU - Tubiana-Hulin, Michèle

AU - Petit, Thierry

AU - Rouanet, Philippe

AU - Jassem, Jacek

AU - Blot, Emmanuel

AU - Becette, Véronique

AU - Farmer, Pierre

AU - André, Sylvie

AU - Acharya, Chaitanya R

AU - Mukherjee, Sayan

AU - Cameron, David

AU - Bergh, Jonas

AU - Nevins, Joseph R

AU - Iggo, Richard D

PY - 2007/12

Y1 - 2007/12

N2 - We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial.

AB - We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Cyclophosphamide

KW - Disease-Free Survival

KW - Epirubicin

KW - Female

KW - Fluorouracil

KW - Gene Expression Profiling

KW - Gene Expression Regulation, Neoplastic

KW - Genetic Testing

KW - Humans

KW - Middle Aged

KW - Neoadjuvant Therapy

KW - Neoplasm Staging

KW - Oligonucleotide Array Sequence Analysis

KW - Patient Selection

KW - Predictive Value of Tests

KW - ROC Curve

KW - Receptors, Estrogen

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Taxoids

KW - Treatment Outcome

U2 - 10.1016/S1470-2045(07)70345-5

DO - 10.1016/S1470-2045(07)70345-5

M3 - Article

C2 - 18024211

SN - 1470-2045

VL - 8

SP - 1071

EP - 1078

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 12

ER -

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this